Clinical experience with BIAsp 30: Results from the Indonesian cohort of the international A1chieve study
Diabetes Research and Clinical Practice, pages S54 - S59
Published online Aug-2013
To evaluate the safety and effectiveness of biphasic insulin aspart 30 (BIAsp 30) in Indonesian patients with type 2 diabetes (T2D) as part of the 24-week, international, prospective, non-interventional A1chieve study.
Indonesian patients who started BIAsp 30 were included. Safety and efficacy was measured as part of routine clinical practice at baseline, Week 12 and Week 24. Results: Overall, 1324 patients having a mean±SD age, duration of diabetes and body mass index of 55.2±9.9 yrs, 6.8±5.2 yrs and 24.1±3.6kg/m2, respectively, were enrolled. 67% of patients were insulin-naive and 33% were prior insulin users. Glycaemic control was poor at baseline. After 24 weeks, significant reductions from baseline were observed in the mean glycated haemoglobin A1c (HbA1c) (–2.6%), fasting plasma glucose (–93.8 mg/dL) and postprandial plasma glucose (–134.8 mg/dL) levels in the entire cohort (p < 0.001). Significant reductions were also seen in insulin-naive patients and prior insulin users. At Week 24, 29.9% of patients in the entire cohort achieved target HbA1c level of <7.0%, while 26.7% and 39.2% achieved this target among insulin-naive patients and prior insulin users, respectively. The proportion of patients reporting overall hypoglycaemia significantly decreased in the entire cohort after 24 weeks of BIAsp 30 therapy. A small significant increase in body weight was noted in the entire cohort, insulin-naive patients and prior insulin users.
The current study suggests that BIAsp 30 can be considered as a safe and effective option for initiating as well as intensifying insulin therapy in Indonesian patients with T2D.
Keywords: Type 2 diabetes, Indonesia, Biphasic insulin aspart 30, A1chieve.
- 1 S Soegondo, IS Widyahening, R Istantho, E Yunir. Prevalence of diabetes among suburban population of Ternate – a small remote island in the eastern part of Indonesia. Acta Med Indones. 2011;43(2):99-104
- 2 JA Mayfield, RD White. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician. 2004;70:489-500
- 3 HW Rodbard, L Blonde, SS Braithwaite, EM Brett, RH Cobin, Y Handelsman, et al., AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13(Suppl 1):1-68 Crossref.
- 4 RC Turner, CA Cull, V Frighi, RR Holman. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012 Crossref.
- 5 SE Inzucchi, RM Bergenstal, JB Buse, M Diamant, E Ferrannini, M Nauck, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55(6):1577-1596 Crossref.
- 6 RR Holman, SK Paul, MA Bethel, DR Matthews, HA Neil. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589 Crossref.
- 7 AR Rolla, RE Rakel. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther. 2005;27(8):1113-1125 Crossref.
- 8 P Valensi. Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes. Diabetes Metab Syndr Obes. 2009;2:61-71
- 9 AJ Garber, J Wahlen, T Wahl, P Bressler, R Braceras, E Allen. Attainment of glycemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab. 2006;8(1):58-66 Crossref.
- 10 P Home, NE Naggar, M Khamseh, G Gonzalez-Galvez, C Shen, P Chakkarwar, et al. An observational non-interventional study of patients with diabetes beginning or changed to insulin analogue therapy in non-Western countries: The A1chieve study. Diabetes Res Clin Pract. 2011;94:352-363 Abstract, Full-text, PDF, Crossref.
- 11 P Soewondo, S Soegondo, K Suastika, A Pranoto, DW Soeatmadji, A Tjokroprawiro. The DiabCare Asia 2008 study – Outcomes on control and complications of type 2 diabetic patients in Indonesia. Med J Indones. 2010;19:235-244 Crossref.
- 12 PH Kann, T Wascher, V Zackova, J Moeller, J Medding, A Szocs, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006;114(9):527-532 Crossref.
- 13 P Valensi, M Benroubi, V Borzi, J Gumprecht, R Kawamori, J Shaban, et al. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract. 2009;63(3):522-531 Crossref.
- 14 WM Bebakar, CC Chow, KA Kadir, S Suwanwalaikorn, JA Vaz, OM Bech. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9(5):724-732 Crossref.
- 15 Y Gao, XH Guo. Switching from human insulin to biphasic insulin aspart 30 treatment gets more patients with type 2 diabetes to reach target glycosylated hemoglobin <7%: the results from the China cohort of the PRESENT study. Chin Med J (Engl). 2010;123(9):1107-1111
- 16 D Khutsoane, SK Sharma, M Almustafa, HC Jang, ST Azar, R Danciulescu, et al. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes Metab. 2008;10(3):212-222 Crossref.
- 17 N Yoshioka, Y Kurihara, N Manda, K Komori, M Kato, H Kijima, et al. Step-up therapy with biphasic insulin aspart-70/30 – Sapporo 1-2-3 study. Diabetes Res Clin Pract. 2009;85(1):47-52 Crossref.
- 18 P Raskin, E Allen, P Hollander, A Lewin, RA Gabbay, P Hu, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265 Crossref.
- 19 A Esteghamati, R Rajabian, M Amini, A Bahrami, ME Khamseh, M Afkhami-Ardekani, et al. The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study – the Iran subgroup of the IMPROVE™ study. Endokrynol Pol. 2010;61(4):364-370
a University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia
b Gadjah Mada University, Sardjito Hospital, Yogyakarta, Indonesia Gadjah Mada University, Sardjito Hospital, Yogyakarta, Indonesia
c Sam Ratulangi University, Prof. Dr. R.D. Kandou Hospital, Manado, Indonesia Sam Ratulangi University, Prof. Dr. R.D. Kandou Hospital, Manado, Indonesia
d Padjajaran University, Hasan Sadikin Hospital, Bandung, Indonesia Padjajaran University, Hasan Sadikin Hospital, Bandung, Indonesia
e Fatmawati General Hospital, Jakarta, Indonesia Fatmawati General Hospital, Jakarta, Indonesia
Corresponding author at: University of Indonesia, Cipto Mangunkusomo Hospital, Jakarta, Indonesia. Tel.: +62 21 390 7703; fax: +62 21 392 8659
© 2013 Published by Elsevier B.V.